Dr Fabio Schutz addresses a key challenge when treating patients with metastatic castration resistant prostate cancer (mCRPC). What do you do if they progress on an androgen receptor (AR) directed therapy?
Oncology
Treating mCRPC patients who have progressed on AR-directed therapy
Publication Date
Oct 2021
Dr Fabio Schutz graduated from Parana Federal University and did his internal medicine residency at Hospital de Clinicas in Curitiba - PR, Brazil. Then, he moved to São Paulo - SP for his medical oncology clinical fellowship at Hospital Sirio Libanes. After finishing his medical oncology fellowship, he worked for a couple of years as an assistant medical oncologist in the same hospital. From 2009 to 2011, he worked as a research fellow in genitourinary (GU) oncology in the Lank Center for GU Oncology at the Dana-Farber Cancer Institute - Harvard Medical School in Boston - MA, USA. He developed several original research projects and authored many manuscripts in high-impact journals. Since mid-2011, he is working as a medical oncologist of the BP - Beneficencia Portuguesa de Sao Paulo in Sao Paulo - SP, Brazil. He is most interested and is currently conducting clinical trials in GU cancers.
Dr Fabio Schutz has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Astellas, Bayer, BMS, Janssen and Ipsen
Programme summary
Duration 5 MIN
Downloadable resources Yes-
DOWNLOAD SLIDES - PDF
-
Language(s)
Share this programme
Brought to you by
GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.
Meet the experts
Other programmes of interest
Video
Oncology
The emerging role of artificial intelligence in precision oncology
Expert opinion on the clinical application of artificial intelligence (AI)
Experts
Prof. Albrecht Stenzinger-
Downloadable
Resources -
6 MIN
-
Nov 2024
Podcast
Oncology
BRAF-mutated CRC: from testing to treatment
Medical experts share insights and review key clinical trials
Experts
Prof. Sebastian Stintzing, Dr Thomas WinderEndorsed by
-
Downloadable
Resources -
25 MIN
-
Nov 2024
Other
Oncology
Biomarker testing in NSCLC: patient and caregiver awareness and understanding
Findings from a global survey presented in a poster at ESMO 2024
Experts
Prof. Christian Rolfo, Prof. Fernando López-Ríos, Dr. Rodrigo Paredes, Amy Moore, Anne-Marie Baird, Shani ShiloEndorsed by
-
Downloadable
Resources -
5 MIN
-
Sep 2024
Podcast
Oncology Rare diseases
Neuroendocrine tumours (NETs) shared decision-making: Exploring the patient journey and individualising treatments
Experts
Dr Mohid S Khan, Sally JenkinsEndorsed by
-
Downloadable
Resources -
23 MIN
-
Sep 2024
Conference update
Oncology
ESMO 2024: New data on GI, lung, HCC, breast and GU cancers
Renowned medical experts share their insights into new data presented at ESMO 2024
-
Downloadable
Resources -
5 MIN
-
Sep 2024
Animated Video
Episode
1
of 1
Oncology
Precision oncology in prostate cancer: tips for optimal genomic testing
From sample collection through to diagnostic modalities
Experts
Dr Alexander WyattEndorsed by
-
Downloadable
Resources -
5 MIN
-
Sep 2024